Clinical and laboratory characteristics of the AML patients when categorized by CXCR4 expression according to low (group A), intermediate (group B), or high (group C) CXCR4 expression
| . | Group A . | Group B . | Group C . | Groups B and C . |
|---|---|---|---|---|
| No. of patients | 32 | 26 | 32 | 58 |
| Prognostic markers | ||||
| Median CXCR4, MFIR (range) | 2.8 (1.2-4.9) | 6.9 (5.1-9.4) | 17.2 (10.3-73.4) | 11.29 (5.1-73.4) |
| Median age, y (range) | 62.0 (21-89) | 59.5 (18-81) | 65.0 (32-93) | 62.5 (18-93) |
| Median WBC count, × 109/L (range) | 4.0 (0.5-124.0) | 14.9 (0.8-300) | 25.2 (0.6-240) | 24.4 (0.8-300) |
| Median platelet count, × 109/L (range) | 56.0 (8-211) | 81.0 (10.0-265) | 82.5 (4-218) | 82 (4-265) |
| Median LDH level, U/L (range) | 251.5 (140-2637) | 380.0 (187-1816) | 357.5 (144-2760) | 376.5 (144-2760) |
| Unfavorable cytogenetics (%) | 6 of 28 (21.43) | 12 of 25 (48.0) | 8 of 27 (29.63) | 20 of 52 (38.46) |
| Variable, no. (%) | ||||
| Cytarabine ± anthracycline-based induction | 18 (56.25) | 19 (73.08) | 14 (43.75) | 33 (56.90) |
| Decitabine | 6 (18.75) | 2 (7.69) | 5 (16.63) | 7 (12.07) |
| Other cytoreductive therapy | 5 (16.63) | 4 (15.38) | 9 (28.13) | 13 (22.41) |
| No therapy | 3 (9.38) | 1 (3.85) | 4 (12.50) | 5 (8.62) |
| Allogenic SCT | 17 (53.13) | 17 (65.38) | 13 (40.63) | 30 (51.72) |
| CR | 25 (78.13) | 19 (73.08) | 16 (50) | 35 (60.34) |
| CR after induction | 13 (40.63) | 7 (26.92) | 4 (12.5) | 11 (18.97) |
| CR after double induction | 0 (0) | 0 (0) | 1 (3.13) | 1 (1.72) |
| CR after low-dose decitabine | 1 (3.13) | 0 (0) | 1 (3.13) | 1 (1.72) |
| CR after allogenic SCT | 11 (34.38) | 12 (46.15) | 10 (31.25) | 22 (37.93) |
| Primary refractory | 5 of 18 (27.78) | 12 of 19 (63.16) | 10 of 14 (71.43) | 22 of 33 (66.66) |
| Relapses | 4 of 25 (16.00) | 12 of 19 (63.16) | 8 of 16 (50) | 20 of 35 (57.14) |
| Total deaths | 10 (31.25) | 17 (65.38) | 20 (62.50) | 37 (63.79) |
| Survival | ||||
| Mean overall survival, mo (SEM) | 24.3 (2.9) | 17.4 (3.4) | 12.8 (2.0) | 15.5 (2.2) |
| Mean relapse-free survival, mo (SEM) | 24.2 (2.4) | 18.7 (3.8) | 11.5 (1.4) | 19.3 (3.0) |
| . | Group A . | Group B . | Group C . | Groups B and C . |
|---|---|---|---|---|
| No. of patients | 32 | 26 | 32 | 58 |
| Prognostic markers | ||||
| Median CXCR4, MFIR (range) | 2.8 (1.2-4.9) | 6.9 (5.1-9.4) | 17.2 (10.3-73.4) | 11.29 (5.1-73.4) |
| Median age, y (range) | 62.0 (21-89) | 59.5 (18-81) | 65.0 (32-93) | 62.5 (18-93) |
| Median WBC count, × 109/L (range) | 4.0 (0.5-124.0) | 14.9 (0.8-300) | 25.2 (0.6-240) | 24.4 (0.8-300) |
| Median platelet count, × 109/L (range) | 56.0 (8-211) | 81.0 (10.0-265) | 82.5 (4-218) | 82 (4-265) |
| Median LDH level, U/L (range) | 251.5 (140-2637) | 380.0 (187-1816) | 357.5 (144-2760) | 376.5 (144-2760) |
| Unfavorable cytogenetics (%) | 6 of 28 (21.43) | 12 of 25 (48.0) | 8 of 27 (29.63) | 20 of 52 (38.46) |
| Variable, no. (%) | ||||
| Cytarabine ± anthracycline-based induction | 18 (56.25) | 19 (73.08) | 14 (43.75) | 33 (56.90) |
| Decitabine | 6 (18.75) | 2 (7.69) | 5 (16.63) | 7 (12.07) |
| Other cytoreductive therapy | 5 (16.63) | 4 (15.38) | 9 (28.13) | 13 (22.41) |
| No therapy | 3 (9.38) | 1 (3.85) | 4 (12.50) | 5 (8.62) |
| Allogenic SCT | 17 (53.13) | 17 (65.38) | 13 (40.63) | 30 (51.72) |
| CR | 25 (78.13) | 19 (73.08) | 16 (50) | 35 (60.34) |
| CR after induction | 13 (40.63) | 7 (26.92) | 4 (12.5) | 11 (18.97) |
| CR after double induction | 0 (0) | 0 (0) | 1 (3.13) | 1 (1.72) |
| CR after low-dose decitabine | 1 (3.13) | 0 (0) | 1 (3.13) | 1 (1.72) |
| CR after allogenic SCT | 11 (34.38) | 12 (46.15) | 10 (31.25) | 22 (37.93) |
| Primary refractory | 5 of 18 (27.78) | 12 of 19 (63.16) | 10 of 14 (71.43) | 22 of 33 (66.66) |
| Relapses | 4 of 25 (16.00) | 12 of 19 (63.16) | 8 of 16 (50) | 20 of 35 (57.14) |
| Total deaths | 10 (31.25) | 17 (65.38) | 20 (62.50) | 37 (63.79) |
| Survival | ||||
| Mean overall survival, mo (SEM) | 24.3 (2.9) | 17.4 (3.4) | 12.8 (2.0) | 15.5 (2.2) |
| Mean relapse-free survival, mo (SEM) | 24.2 (2.4) | 18.7 (3.8) | 11.5 (1.4) | 19.3 (3.0) |
Because patients with intermediate and high CXCR4 expression did not significantly differ in terms of OS and RFS, we combined the data for these patients in the right-hand column labeled “B + C.” Unless stated otherwise, the percentages refer to the absolute number of patients in the respective groups that are displayed in the top row. Cytogenetic results were not available for all patients (only for 28 of 32 patients in group A, 25 of 26 in group B, and 27 or 32 in group C), and the percentages are adjusted accordingly. Patients were considered primary refractory only if they had received cytarabine/anthracycline-based inducion therapy (18 of 32 in group A, 19 of 26 in group B, and 14 of 32 in group C), and the percentages refer to these numbers. Moreover, patients were considered to be relapsed only if they had achieved a prior CR (25 of 32 in group A, 19 of 26 in group B, and 16 of 32 in group C).